New Pill-and-Infusion combo shows promise for lymphoma patients
NCT ID NCT01316523
First seen Nov 21, 2025 · Last updated May 07, 2026 · Updated 15 times
Summary
This study tested a combination of two drugs—lenalidomide (a daily pill) and rituximab (an infusion)—in 30 adults with untreated, slow-growing non-Hodgkin's lymphoma. The goal was to see how well the combo shrinks or eliminates tumors. Participants took lenalidomide for 21 days each month and received rituximab infusions weekly for four weeks, with a possible second course. The study was stopped early, but results help guide future treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sutter Pacific Medical Foundation
Santa Rosa, California, 95403, United States
-
University of California Davis Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.